Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX-471 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Compass Therapeutics
  • Most Recent Events

    • 05 Jan 2024 Response in 5 patients observed, were presented in a Compass Therapeutics Media Release.
    • 05 Jan 2024 According to a Compass Therapeutics media release, dose-escalation portion of the study has been fully enrolled and enrollment in the dose expansion cohorts has begun, 60 patients with melanoma, NSCLC and SCLC will be enrolled in the dose-expansion cohort, who will be randomized into two doses.
    • 15 Mar 2023 According to Compass Therapeutics media release, initial combination results are expected in the second half of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top